Reducing the risk of potential ICS adverse events was more important to patients with better disease status than to patients with worse disease status (for asthma, RI for 5-year risk of osteoporosis=0.18 for ACQ≤0.75, 0.10 for 0.75<ACQ<1.5 and 0.13 for ACQ≥1.5; for COPD, RI for 5-year risk of pneumonia=0.24 for CAT ≤20, 0.21 for 20<CAT <30 and 0.16 for CAT ≥30). Here, CAT is linked to asthma.